Mohammed bin Rashid funds Dh8.8m SMA treatment at Al Jalila, testing rare-disease pathways

Sheikh Mohammed bin Rashid Al Maktoum will fund about Dh8.8 million in treatment for Katia Abu Al Saud, a Jordanian toddler with spinal muscular atrophy, at Al Jalila Children’s Hospital in Dubai.

The story, reported by Emirates 24|7 and other UAE media, matters beyond one family. For Dubai clinics, insurers and patients, it shows how a rare paediatric diagnosis can move from social-media appeal to tertiary referral when the required therapy is outside a family’s financial reach.

What happened

Dubai Media Office said on 20 August 2026 that Sheikh Mohammed, Vice President and Prime Minister of the UAE and Ruler of Dubai, would cover Katia’s treatment. The National reported on 21 August 2026 that Katia is 16 months old, remains in Jordan, and is expected to receive care at Al Jalila Children’s Hospital after the family travels to the UAE.

The treatment cited in the reports is Zolgensma, a one-time gene therapy for spinal muscular atrophy. The reported cost was $2.4 million, or about Dh8.8 million. The National reported that Zolgensma is mainly administered to children under two years old, a practical eligibility point for paediatricians and referral teams assessing suspected SMA cases.

“Thank you very much for saving my daughter’s life before it was too late.”
Nour Roudnahal, Katia’s mother, in a message reported by Al Jadeed

The UAE regulatory map is straightforward for operators. Dubai Health Authority (DHA) regulates Dubai facilities, including private-sector referral and licensing obligations. Department of Health Abu Dhabi (DOH) regulates Abu Dhabi and Al Ain. Ministry of Health and Prevention (MOHAP) covers the northern emirates. Drug registration and availability sit with the federal medicines framework, now centred on the Emirates Drug Establishment.

Why UAE operators should care

For chief operating officers and medical directors, the case is a referral-speed issue. SMA treatment eligibility can depend on age, genetic confirmation and clinical status. A Dubai clinic that sees hypotonia, delayed motor milestones or feeding weakness in an infant should have a written pathway for urgent paediatric neurology referral, genetic testing documentation and insurer pre-authorisation. The relevant clock is measured in weeks, not quarters.

For chief financial officers and insurer relations teams, the Dh8.8 million figure is the commercial fact. It sits outside normal outpatient paediatrics economics. Operators should separate three questions before quoting families: whether the therapy is registered and available in the UAE, whether the treating facility can administer it, and whether the payer will treat it as covered, exceptional, charitable or self-pay care.

• Dubai providers should check DHA licensing scope and referral relationships for paediatric neurology, genetics and tertiary hospital admission.
• Abu Dhabi and Al Ain providers should check DOH-licensed tertiary options and payer rules before promising transfer timelines.
• Northern emirates providers should confirm MOHAP facility licensing and whether the case needs Dubai or Abu Dhabi referral.
• Insurers should publish case-manager contact routes for rare-disease escalation, because families rarely know which documents decide approval.

For patients, the case shows why “covered” is too vague for rare disease. Families should ask for the diagnosis code, genetic test report, treatment name, facility name, estimated drug cost, hospital administration cost and written payer decision. If a clinic cannot provide those documents, the family cannot compare options or appeal a denial.

What to watch next

The immediate next point is whether Katia travels to Dubai and receives treatment at Al Jalila Children’s Hospital within the age window reported for Zolgensma. The wider issue is whether UAE payers create clearer rare-disease pathways after a public case with a Dh8.8 million price tag.

Clinics should audit their paediatric neurology referral process in 2026, starting with suspected SMA, Duchenne muscular dystrophy and other genetic disorders where treatment timing affects eligibility. Insurers should test whether call-centre staff can route a rare-disease request to a medical case manager within one working day.

Families and operators looking for licensed paediatric care can use the UAE Open Healthcare Directory, which lists 12,384+ licensed providers across eight UAE cities and includes 144 pediatrics listings sourced from official government registers.